Female Reproductive Sites 11/8/07

NAACCR Central Registry Webinar Series

Shannon Vann, CTR
Jim Hofferkamp, CTR

Female Reproductive System Cancer Surveillance Data Collection

Structures of Female Pelvis

Source: Collaborative Staging Steering Committee Training Materials for Ovary
Structures of the Female Pelvis

- Perimetrium
  - Serosa of uterine body
- Parametrium
  - Connective tissue of the pelvic floor

Image Source: http://www.bodytherapyassociates.com
Peritoneum

Image source: http://mywebpages.comcast.net/wnor/peritoneum.htm

The Ovaries

Image Source: SEER Training Website

Ovarian Tissue

Image Credits: NAACCR
Cancer Histology of the Cervix

- Squamous cell carcinoma (8070/3)
  - Arises mostly in lower third of cervix
  - 90% of all cervical cancers
  - Also called epidermoid carcinoma
- Adenocarcinoma (8140/3)
  - 10% of all cases
- Adenosquamous carcinoma (8560/3)
  - Mixed adenocarcinoma and epidermoid carcinoma
- Small cell carcinoma (8041/3)
- Sarcoma (cell types vary)
- Lymphoma (many cell types)

Cancer Histology of the Cervix

- Cervical Intraepithelial Neoplasia (CIN)
- Carcinoma In Situ of the Cervix
  - Bowen's disease
  - Stage 0
  - CIN grade III
  - Confined to epithelium
  - Intraepidermal
  - Intraepithelial
  - Involvement up to, but not including the basement membrane
  - Noninfiltrating
  - Noninvasive
  - No stromal involvement
  - Papillary noninfiltrating

PAP and HPV Test

- Cytological study of epidermal cells
- Used to detect cancer and changes that may lead to cancer
- HPV infection is the primary risk factor for cervical cancer
Cancer Histology for Uterine Body

- Endometrium
  - Adenocarcinoma
  - Clear cell carcinoma
  - Papillary carcinoma
  - Adenosquamous carcinoma
- Myometrium
  - Sarcoma
    - Leiomyosarcoma

Ovarian Cancer Histology

Pelvic Organs

- Adnexae - “appendages” of the uterus, namely the ovaries, Fallopian tubes and ligaments that hold the uterus in place
  - Bladder
  - Bladder Serosa
  - Broad Ligament
  - Cul-de-sac
  - Fallopian Tubes
  - Parametrium

Pelvic Peritoneum
- Pelvic wall
- Rectum
- Sigmoid Colon
- Sigmoid Mesentery
- Ureter
- Uterus
- Uterine Serosa
Abdominal Organs

- Abdominal Mesentery
- Diaphragm
- Gallbladder
- Infracolic omentum
- Kidneys
- Large Intestine
  - Except rectum and sigmoid
- Liver (peritoneal surface only)
- Omentum
- Pancreas
- Pericolic gutter
- Peritoneum, NOS
- Small Intestine
- Spleen
- Stomach
- Ureters

Collaborative Staging for Cervix Uteri

Note
- Code largest measurement of horizontal spread or surface diameter
- Code depth of invasion in CS Extension

CS Tumor Size Cervix Uteri
### CS Tumor Size

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No mass/tumor found</td>
</tr>
<tr>
<td>001-988</td>
<td>Exact size in millimeters</td>
</tr>
<tr>
<td>989</td>
<td>989 mm or larger</td>
</tr>
<tr>
<td>990</td>
<td>Microscopic focus</td>
</tr>
<tr>
<td>991</td>
<td>Described as ‘less than 1 cm’</td>
</tr>
<tr>
<td>992</td>
<td>Described as ‘less than 2 cm’ or ‘greater than 1 cm’ or ‘between 1 cm and 2 cm’</td>
</tr>
<tr>
<td>993</td>
<td>Described as ‘less than 3 cm’ or ‘greater than 2 cm’ or ‘between 2 cm and 3 cm’</td>
</tr>
<tr>
<td>994</td>
<td>Described as ‘less than 4 cm’ or ‘greater than 3 cm’ or ‘between 3 cm and 4 cm’</td>
</tr>
<tr>
<td>995</td>
<td>Described as ‘less than 5 cm’ or ‘greater than 4 cm’ or ‘between 4 cm and 5 cm’</td>
</tr>
<tr>
<td>999</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
FIGO Stage for Cervix Uteri

- FIGO Stage I
  - Confined to uterus
- FIGO Stage II
  - Beyond uterus but not pelvic wall or lower third of vagina
- FIGO Stage III
  - Lower third of vagina or pelvic wall or hydronephrosis
- FIGO Stage IVA
  - Mucosa of bladder or rectum or beyond true pelvis
- FIGO Stage IVB
  - Distant metastasis

CS Extension Cervix Uteri

**Notes**

- Note 1: Involvement of anterior and/or posterior septum is coded as involvement of the vaginal wall.
- Note 2: Record positive pelvic or peritoneal washings as information only. Not to be coded as metastatic disease.

CS Extension Cervix Uteri

- 00 In situ
- 01 CIN (Cervical intraepithelial neoplasia) Grade III
- 11 Minimal microscopic stromal invasion
  - Less than or equal to 3 mm in depth and less than or equal to 7 mm in horizontal spread
  - FIGO Stage IA1
CS Extension Cervix Uteri

12 "Microinvasion"
- Tumor WITH invasive component greater than 3 mm and less than or equal to 5 mm in depth, taken from the base of the epithelium, and less than or equal to 7 mm in horizontal spread
- FIGO Stage IA2

CS Extension Cervix Uteri

20 Invasive cancer confined to cervix and tumor larger than that in code 12
- FIGO Stage IB

25 Invasive cancer confined to cervix and clinically visible lesion

CS Extension Cervix Uteri

30 Localized, NOS
- Confined to cervix uteri or uterus, NOS, except corpus uteri, NOS
  (Not clinically visible or unknown if clinically visible.)
- FIGO Stage I, not further specified

35 Corpus uteri, NOS T1NOS
CS Extension Cervix Uteri
- 36 Code (35) + (11)
- 37 Code (35) + (12)
- 38 Code (35) + [(20) or (25)]
- 39 Code (35) + [(30) or (31)]

CS Extension Cervix Uteri
- 40 Extension to:
  - Cul de sac (rectouterine pouch)
  - Upper 2/3’s of vagina including fornices
  - Vagina, NOS
  - Vaginal wall, NOS
  - FIGO Stage IIA
  - FIGO Stage II, NOS

CS Extension Cervix Uteri
- 50 Extension to:
  - Ligament(s):
    - Broad
    - Cardinal
    - Uterosacral
  - Parametrium (paracervical soft tissue)
  - FIGO Stage IIB
CS Extension Cervix Uteri

- 60 Extension to:
  - Bladder wall
  - Bladder, NOS excluding mucosa
  - Bullous edema of bladder mucosa
  - Lower 1/3 of vagina
  - Rectal wall
  - Rectum, NOS excluding mucosa
  - FIGO Stage IIIA

CS Extension Cervix Uteri

- 62 Extension to:
  - Ureter, intra- and extramural
  - Vulva
  - FIGO Stage IIIA
- 63 Tumor causes hydronephrosis or nonfunctioning kidney
  - FIGO Stage IIIB

CS Extension Cervix Uteri

- 65 Extension to pelvic wall(s)
  - (Described clinically as "frozen pelvis", NOS)
  - FIGO Stage IIIB
- 68 Extension to:
  - Fallopian tube
  - Ovary(ies)
  - Urethra
  - FIGO Stage III, NOS
**CS Extension Cervix Uteri**

- 70 Extension to rectal or bladder mucosa
  - (Note: for bullous edema of bladder mucosa, see code 60.)
  - FIGO Stage IVA

- 80 Further contiguous extension beyond true pelvis
  - Sigmoid colon
  - Small intestine
  - FIGO Stage IVA, not further specified

---

**CS Extension Cervix Uteri**

- 95 No evidence of primary tumor
- 99 Unknown extension
  - Primary tumor cannot be assessed
  - Not documented in patient record

---

**CS Tumor Size/Ext Eval Cervix Uteri**

- Note
  - If cone biopsy removes all tumor, assign CS tumor size/extension eval code 3
  - If cone biopsy leaves residual tumor, assign CS tumor size extension eval code 1
### CS Tumor Size/Ext Eval

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Clinical only</td>
</tr>
<tr>
<td>1</td>
<td>Invasive techniques</td>
</tr>
<tr>
<td>2</td>
<td>Autopsy (known or suspected dx)</td>
</tr>
<tr>
<td>3</td>
<td>Pathology</td>
</tr>
<tr>
<td>5</td>
<td>Pre-op tx; clinical eval</td>
</tr>
<tr>
<td>6</td>
<td>Pre-op tx; pathologic eval</td>
</tr>
<tr>
<td>8</td>
<td>Autopsy; dx not suspected</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### CS Lymph Nodes Cervix Uteri

- **00** None
- **10** Regional lymph nodes:
  - Iliac, NOS:
    - Common
    - External
    - Internal - Obturator
  - Paracervical
  - Parametrial

*Image Source: SEER Training Website*

### CS Lymph Nodes Cervix Uteri (cont.)

- **10** Regional lymph nodes (cont.):
  - Pelvic, NOS
  - Sacral, NOS:
    - Lateral
    - Middle
    - Presacral
    - Uterosacral
  - Regional lymph node(s), NOS

*Image Source: SEER Training Website*
### CS Lymph Nodes Cervix Uteri
- 80 Lymph nodes, NOS
- 99 Unknown

### CS Reg Node Eval

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Clinical only</td>
</tr>
<tr>
<td>1</td>
<td>Invasive techniques</td>
</tr>
<tr>
<td>2</td>
<td>Autopsy (known or suspected dx)</td>
</tr>
<tr>
<td>3</td>
<td>Pathology</td>
</tr>
<tr>
<td>5</td>
<td>Pre-op tx; clinical eval</td>
</tr>
<tr>
<td>6</td>
<td>Pre-op tx; pathologic eval</td>
</tr>
<tr>
<td>8</td>
<td>Autopsy; dx not suspected</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Regional Nodes Positive

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Nodes negative</td>
</tr>
<tr>
<td>01-89</td>
<td>1-89 nodes positive</td>
</tr>
<tr>
<td>95</td>
<td>90 or more nodes positive</td>
</tr>
<tr>
<td>95</td>
<td>Positive aspiration or core biopsy of LN</td>
</tr>
<tr>
<td>97</td>
<td>Positive nodes, number unspecified</td>
</tr>
<tr>
<td>98</td>
<td>No nodes examined</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Regional Nodes Examined

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No nodes examined</td>
</tr>
<tr>
<td>01-89</td>
<td>1-89 nodes examined</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes examined</td>
</tr>
<tr>
<td>95</td>
<td>No regional nodes removed, but aspiration or core biopsy of lymph nodes</td>
</tr>
<tr>
<td>96</td>
<td>Regional node sampling, number unknown</td>
</tr>
<tr>
<td>97</td>
<td>Regional node dissection, number unknown</td>
</tr>
<tr>
<td>98</td>
<td>Regional nodes removed, number unknown, not documented as sampling or dissection; nodes examined, number unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

CS Mets Cervix Uteri

- 00 None
- 10 Distant lymph node(s) including:
  - Aortic (para-, peri-, lateral), Inguinal (femoral), Mediastinal
  - Distant lymph node(s), NOS
  - FIGO Stage IV
- 40 Distant metastases except distant lymph node(s) (code 10)
  - Distant metastasis, NOS
  - Carcinomatosis
- 50 (10) to (40)
  - Distant lymph node(s) plus other distant metastases
- 99 Unknown if distant metastasis
  - Distant metastasis cannot be assessed
  - Not documented in patient record
CS Mets Eval

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Clinical only</td>
</tr>
<tr>
<td>1</td>
<td>Invasive techniques</td>
</tr>
<tr>
<td>2</td>
<td>Autopsy (known or suspected dx)</td>
</tr>
<tr>
<td>3</td>
<td>Pathology</td>
</tr>
<tr>
<td>5</td>
<td>Pre-op tx; clinical eval</td>
</tr>
<tr>
<td>6</td>
<td>Pre-op tx; pathologic eval</td>
</tr>
<tr>
<td>8</td>
<td>Autopsy; dx not suspected</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

CS Site-Specific Factors 1-6
Cervix Uteri

- Assign code 888
- Not applicable for this site

Collaborative Staging for Uterine Body Cancer
**FIGO Stage for Uterine Body**

<table>
<thead>
<tr>
<th>FIGO</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>In situ</td>
</tr>
<tr>
<td>I</td>
<td>Tumor confined to uterine body</td>
</tr>
<tr>
<td>II</td>
<td>Tumor invades cervix but does not extend beyond uterus</td>
</tr>
<tr>
<td>III</td>
<td>Local and regional spread as specified in IIIA and IIIB</td>
</tr>
<tr>
<td>IVA</td>
<td>Tumor invades bladder mucosa and/or bowel mucosa</td>
</tr>
</tbody>
</table>

**CS Extension Uterine Body**

Notes
1. Extension to bowel or bladder mucosa must be proven by biopsy.
2. It is unclear to which stage previous cases were coded because cancer cells in ascites or peritoneal washings was not specifically categorized in SS77.

**CS Extension Uterine Body**

- Code 00
  - In situ; pre-invasive; non-invasive; intraepithelial
  - Cancer in situ
  - FIGO stage 0
- Code 10
  - FIGO stage I
  - Confined to uterine body
CS Extension

Uterine Body

Code 11:
Confined to endometrium; FIGO IA

Image Source: http://www.nuff.org

Code 12:
Tumor invades < one-half of myometrium; inner half of myometrium; FIGO IB

Image Source: http://www.nuff.org

Code 13:
Tumor invades one-half or more of myometrium; outer half of myometrium; FIGO IC

Image Source: http://www.nuff.org
CS Extension
Uterine Body

- Code 14
  - Invasion of myometrium, NOS
- Code 16
  - Tunica serosa of visceral peritoneum (perimetrium)

CS Extension
Uterine Body

- Code 40
  - Localized, NOS
- Code 50
  - Cervix uteri, NOS
  - FIGO Stage II, NOS

CS Extension
Uterine Body

- Code 51: Endocervical gland involvement; FIGO IIA
- Code 52: Cervical stromal invasion; FIGO IIB

Image Source: SEER Training Website
CS Extension Uterine Body

Code 60: Extension or metastasis within true pelvis; FIGO IIIA, FIGO III, NOS

Image Source: http://www.theodora.com

CS Extension Uterine Body

Code 61: Cancer cells in ascites; cancer cells in peritoneal washings; FIGO IIIA

Image Source: http://www.cancerhelp.org.uk

CS Extension Uterine Body

Code 62: Ureter and vulva

Image Source: http://www.med.mun.ca
CS Extension
Uterine Body

Code 64: Extension or metastasis to vagina; FIGO IIIB

CS Extension
Uterine Body

Code 66: Extension or metastasis to pelvic wall; clinically frozen pelvis
Code 66: Extension or metastasis to bladder wall or rectal wall
Code 87: (65) or (66) and (62) or (64)

CS Extension
Uterine Body

- Code 70
  - Extension to bowel mucosa or bladder mucosa
  - FIGO IVA
  - FIGO IV, NOS
- Code 80
  - Further contiguous extension
- Code 95
  - No evidence of primary tumor
- Code 99
  - Unknown
CS Lymph Nodes Uterine Body

Notes

1. Code distant nodes in Mets at Dx
2. If there is a statement that “adnexa palpated” with no mention of lymph nodes, assume lymph nodes are not involved (code 00)
3. If exploratory or definitive surgery with no mention of nodes, assume nodes are negative (code 00)
4. Regional nodes include bilateral and contralateral involvement of named nodes

Source: TNM-Interactive, UICC, 1998

<table>
<thead>
<tr>
<th>Code</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>Hypogastric (internal iliac) Obturator</td>
</tr>
<tr>
<td>20</td>
<td>Common iliac</td>
</tr>
<tr>
<td>30</td>
<td>External iliac</td>
</tr>
<tr>
<td>40</td>
<td>Lateral sacral</td>
</tr>
<tr>
<td>50</td>
<td>Para-aortic Mets at Dx</td>
</tr>
<tr>
<td>60</td>
<td>Inguinal</td>
</tr>
<tr>
<td>50</td>
<td>Regional lymph nodes: FIGO Stage IIIC, NOS</td>
</tr>
<tr>
<td>80</td>
<td>Regional lymph nodes, NOS</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Source: TNM-Interactive, UICC, 1998
CS Mets at Dx
Uterine Body

- **Code 00**
  - None
- **Code 11**
  - Distant lymph nodes
    - Superficial inguinal
- **Code 12**
  - Distant lymph nodes other than code 11
    - Deep inguinal, NOS
    - Distant lymph nodes, NOS

CS Mets at Dx
Uterine Body

- **Code 40**
  - Distant metastases except distant lymph nodes
  - Distant metastasis, NOS
  - Carcinomatosis
  - Stage IVB
  - Stage IV, NOS

CS Mets at Dx
Uterine Body

- **Code 50**
  - (40) + any of [((11) or (12)]
- **Code 99**
  - Unknown
CS Site-Specific Factors 1-6
Uterine Body

- Assign code 888
- Not applicable for this site

Collaborative Staging for Ovarian Cancer

FIGO Stage for Ovary

<table>
<thead>
<tr>
<th>FIGO</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumor confined to ovaries</td>
</tr>
<tr>
<td>II</td>
<td>Tumor involves 1 or both ovaries with pelvic extension</td>
</tr>
<tr>
<td>III</td>
<td>Tumor involves 1 or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis</td>
</tr>
<tr>
<td>IV</td>
<td>Distant metastasis beyond the peritoneal cavity</td>
</tr>
</tbody>
</table>
**CS Extension Ovary: Notes**

1. Malignant ascites change FIGO I and II to IC and IIC
   *Disregard negative ascites or ascites, NOS*

2. Extension to and/or discontinuous metastasis to pelvic organs is FIGO II and CS extension codes 50-65.
   *Involvement may be direct or discontinuous*

3. Implants outside the pelvis (70-73) must be microscopically confirmed

---

4. Determine whether implants are in pelvis (code 60-64) or abdomen (code 70-73) or unspecified (code 75)

5. Extension to and/or discontinuous metastasis to abdominal organs is FIGO III and CS extension codes 70-75

6. Liver parenchymal metastases are coded in Mets at Dx

7. It is unclear to which stage previous cases were coded because cancer cells in ascites or peritoneal washings was not specifically categorized in SS77

---

7. It is unclear to which stage previous cases were coded because cancer cells in ascites or peritoneal washings was not specifically categorized in SS77

8. Assign CS extension code 99 to benign/borderline ovarian tumors that are reportable by agreement to a registry
CS Extension Ovary

**Code 00**
- In situ; pre-invasive; non-invasive; intraepithelial


---

CS Extension Ovary

**Code 10**: One ovary, capsule intact, no tumor on surface, negative ascites; FIGO IA


---

CS Extension Ovary

**Code 20**: Both ovaries, capsules intact, no tumor on surface, negative ascites; FIGO IB

CS Extension Ovary

- Code 30
  - Localized, NOS
  - FIGO Stage I
- Code 35
  - Tumor limited to ovary(ies), capsule(s) ruptured
  - FIGO Stage IC
- Code 36
  - Tumor on ovarian surface
  - FIGO Stage IC

CS Extension Ovary

- Code 41
  - Tumor limited to ovaries with malignant ascites
  - FIGO Stage IC
- Code 43
  - (35) + (41)
  - FIGO Stage IC
- Code 44
  - (36) + any of [(35) or (41)]
  - FIGO Stage IC

CS Extension Ovary

FIGO IIA
Negative ascites
Extension to or implants on:
Code 50: Adnexa/tubes, ipsilateral
Code 52: Adnexa/tubes, contralateral; uterus


CS Extension Ovary

FIGO IIB
Negative ascites
Extension to or implants on:
Code 60: Other ipsilateral pelvic structures*
Code 61: Other contralateral pelvic structures*
* ligaments, mesovarium, pelvic wall, adjacent peritoneum


CS Extension Ovary

- FIGO IIC
  - Tumor confined to pelvis with positive ascites
    - Code 62: [(50) and/or (60)]
    - Code 63: [(52) and/or (60)]
    - Code 64: (61)
- FIGO II, NOS
  - Code 65: Tumor involves one or both ovaries with pelvic extension
Liver Involvement

CS Extension codes 70-73 Mets at Dx code 40

### CS Extension Ovary

<table>
<thead>
<tr>
<th>Code 73</th>
<th>Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside of pelvis, NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 75</td>
<td>Peritoneal implants, NOS</td>
</tr>
</tbody>
</table>

### CS Extension Ovary

<table>
<thead>
<tr>
<th>Code 80</th>
<th>Further contiguous extension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 95</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Code 99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### CS Lymph Nodes Ovary: Notes

1. Code distant nodes in Mets at Dx
2. If there is a statement “adnexa palpated” with no mention of lymph nodes, assume lymph nodes are not involved (code 00)
3. If exploratory or definitive surgery with no mention of nodes, assume nodes are negative (code 00)
4. Regional nodes include bilateral and contralateral involvement of named nodes
CS Lymph Nodes Ovary

- **Code 00**
  - None

- **Code 10**
  - 1 Hypogastric (internal iliac)
  - Obturator

- **Code 11**
  - 2 Common iliac

- **Code 12**
  - 3 External iliac

- **Code 20**
  - 4 Lateral sacral

- **Code 30**
  - 5 Para-aortic

- **Code 40**
  - 6 Inguinal

Source: TNM-Interactive, UICC, 1998
CS Mets at Dx Ovary
- Code 00
  - None
- Code 10
  - Distant lymph nodes

CS Mets at Dx Ovary
- Code 40
  - Distant metastases except distant lymph nodes
    - Liver parenchymal metastasis
    - Pleural effusion with positive cytology
- Code 50
  - (10) + (40)
- Code 99
  - Unknown

CS Site-Specific Factor 1
Ovary (CA-125)
- Record results of carbohydrate antigen 125 (CA-125, cancer antigen 125)
- Considered tumor marker
- Normal range is < 35 U/ml (SI: < 35 kU/L)
- Code highest pre-treatment test value
CS Site-Specific Factor 1
Ovary (CA-125)
- Code 000: Test not done
- Code 010: Positive/elevated
- Code 020: Negative/normal
- Code 030: Borderline
- Code 080: Ordered but results not in chart
- Code 999: Unknown

CS Site-Specific Factors 2-6
Ovary
- Assign code 888
  - Not applicable for this site

Female Reproductive System Cancer Surveillance Data Collection
Diagnostic Procedures

- Colposcopy with biopsy
  - Colposcope used to view abnormal cervical changes.
  - Biopsy of abnormal area may be taken
- Dilation and Curettage (D&C)
  - Can be used to detect cancer of the uterus.
  - Coded as a diagnostic and staging procedure

First Course Treatment

Female Reproductive System

- Intended to affect tumor by
  - Modification
  - Control
  - Removal
  - Destruction
- Includes curative and palliative treatment
### Surgical Procedure of Primary Site: Female Reproductive System Sites

- **Site-specific codes**
  - Cervix Uteri (C53.0-C53.9)
    - FORDS Appendix B pages 271-272
    - SEER Program Coding and Staging Manual 2004 pages C-509 - C-510
  - Corpus uteri (C54.0 – C54.9, C55.9)
    - FORDS Appendix B pages 273 - 274
    - SEER Program Coding and Staging Manual 2004 pages C-511 - C-512
  - Ovary (C56.9)
    - FORDS p Appendix B pages 275 - 276
    - SEER Program Coding and Staging Manual 2004 pages C-519 - C-520

### Surgical Procedure of Primary Site: Cervix Uteri

- 16 Laser ablation (no pathology)
- 27 Cone biopsy
- 24 Cone biopsy w/ gross excision
- 29 Trachelectomy; removal of cervical stump; cervicectomy
  - 21 Electrocautery
  - 22 Cryosurgery
  - 23 Laser Ablation or excision
Surgical Procedure of Primary Site: Cervix Uteri

- 25 Dilation and Currettage (for in situ cancers only)
- 28 Loop Electrocautery Excision Procedure (LEEP)

Surgical Procedure of Primary Site: Corpus Uteri

Code 00

- None; no surgery of primary site; autopsy only
Surgical Procedure of Primary Site: Corpus Uteri

- Code 19
  - Local tumor destruction or excision, NOS
    - Principally for cases diagnosed prior to 1/1/2003

Surgical Procedure of Primary Site: Corpus Uteri

- Codes 10 – 16
  - Local tumor destruction without pathology specimen
  - Code 10: NOS
  - Code 11: Photodynamic therapy (PDT)
  - Code 12: Electrocautery; fulguration
  - Code 13: Cryosurgery

Surgical Procedure of Primary Site: Corpus Uteri

- Codes 10 – 16 (cont.)
  - Local tumor destruction without pathology specimen
  - Code 14: Laser
    - Photoablation
    - Photocoagulation
  - Code 15: Loop electrocautery/electrosurgical excision procedure (LEEP)
  - Code 16: Thermal ablation
    - Thermal balloon ablation
    - Radiofrequency thermal ablation
Surgical Procedure of Primary Site: Corpus Uteri

- Code 15: LEEP

Surgical Procedure of Primary Site: Corpus Uteri

- Codes 20 – 26
  - Local tumor excision with pathology specimen
  - Code 20: NOS
  - Code 24: Excisional biopsy
  - Code 25: Polypectomy
  - Code 26: Myomectomy
    - Celiomyomectomy
    - Laparomyomectomy
    - Colpomyomectomy

Surgical Procedure of Primary Site: Corpus Uteri

- Codes 20 – 26 (continued)
  - Any combination of 20 or 24-26 WITH
    - Code 21: Electrocautery
    - Code 22: Cryosurgery
    - Code 23: Laser ablation or excision
Surgical Procedure of Primary Site: Corpus Uteri

Code 26: Myomectomy

Surgical Procedure of Primary Site: Corpus Uteri

- Code 30 - 32
  - Subtotal hysterectomy
  - Code 30: WITH or WITHOUT removal of tubes and ovaries
  - Code 31: WITHOUT tubes and ovaries
  - Code 32: WITH tubes and ovaries

Surgical Procedure of Primary Site: Corpus Uteri

Code 31: Subtotal hysterectomy w/o tubes & ovaries
Surgical Procedure of Primary Site: Corpus Uteri

Code 40:
- Total hysterectomy WITHOUT removal of tubes and ovaries

Code 50:
- Total hysterectomy WITH removal of tubes and ovaries
Surgical Procedure of Primary Site: Corpus Uteri

- Code 60
  - Code 61: Modified radical hysterectomy
    - Telinde operation
  - Code 62: Extended hysterectomy
  - Code 63: Radical hysterectomy
    - Wertheim procedure
    - Schauta operation
    - Type III hysterectomy
  - Code 64: Extended radical hysterectomy

Surgical Procedure of Primary Site: Corpus Uteri

- Code 63: Radical hysterectomy

Surgical Procedure of Primary Site: Corpus Uteri

- Code 65 - 67
  - Hysterectomy, NOS
  - Code 65: WITH or WITHOUT removal of tubes and ovaries
  - Code 66: WITHOUT removal of tubes and ovaries
  - Code 67: WITH removal of tubes and ovaries
Surgical Procedure of Primary Site: Corpus Uteri

- Code 75 - 79
  - Pelvic exenteration
  - Code 75: NOS
  - Code 76: Anterior exenteration
  - Code 77: Posterior exenteration
  - Code 78: Total exenteration
  - Code 79: Extended exenteration

Surgical Procedure of Primary Site: Ovary

- Code 17
  - Local tumor destruction, NOS, without pathology specimen
Surgical Procedure of Primary Site: Ovary

- **Code 25 - 28**
  - Total removal of tumor or (single) ovary
  - Code 25: NOS
  - Code 26: Resection of ovary (wedge, subtotal, or partial) ONLY; unknown if hysterectomy was done
  - Code 27: WITHOUT hysterectomy
  - Code 28: WITH hysterectomy

Surgical Procedure of Primary Site: Ovary

- **Codes 35 - 37**
  - Unilateral (salpingo-)oophorectomy
  - Code 35: unknown if hysterectomy was done
  - Code 36: WITHOUT hysterectomy
  - Code 37: WITH hysterectomy

Surgical Procedure of Primary Site: Ovary

- Code 37: USO with hysterectomy
Surgical Procedure of Primary Site: Ovary

- Codes 50 - 52
  - Bilateral (salpingo-)oophorectomy
  - Code 50: unknown if hysterectomy was done
  - Code 51: WITHOUT hysterectomy
  - Code 52: WITH hysterectomy

- Codes 55 - 57
  - Unilateral or bilateral (salpingo-) oophorectomy WITH OMENTECTOMY; partial or total
  - Code 55: unknown if hysterectomy was done
  - Code 56: WITHOUT hysterectomy
  - Code 57: WITH hysterectomy
Surgical Procedure of Primary Site: Ovary

- Code 60 - 63
  - Debulking; cytoreductive surgery
  - Tumor reduction surgery
  - Code 60: NOS
  - Code 61: WITH colon and/or small intestine resection
  - Code 62: WITH partial resection of urinary tract
  - Code 63: Combination of 61 and 62

- Code 70 - 74
  - Pelvic exenteration
  - Code 70: NOS
  - Code 71: Anterior exenteration
  - Code 72: Posterior exenteration
  - Code 73: Total exenteration
  - Code 74: Extended exenteration

- Code 80
  - (Salpingo-)oophorectomy, NOS
**Female Reproductive Sites**

### Surgical Procedure of Primary Site: Corpus Uteri; Ovary

- **Code 90**
  - Surgery, NOS
- **Code 99**
  - Unknown if surgery performed

### Scope of Regional Lymph Node Surgery Codes*:

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>Biopsy or aspiration of regional LNs, NOS</td>
</tr>
<tr>
<td>2</td>
<td>Sentinel LN biopsy</td>
</tr>
<tr>
<td>3</td>
<td>Number of regional LNs removed unknown</td>
</tr>
<tr>
<td>4</td>
<td>1-3 regional LNs removed</td>
</tr>
<tr>
<td>5</td>
<td>4 or more regional LNs removed</td>
</tr>
<tr>
<td>6</td>
<td>Sentinel biopsy and code 3, 4, or 5 at same time or timing not stated</td>
</tr>
<tr>
<td>7</td>
<td>Sentinel biopsy and code 3, 4, or 5 at different times</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

*FORDS Page 138

### Surgical Procedure/Other Site Codes*:

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>Nonprimary surgical procedure performed</td>
</tr>
<tr>
<td>2</td>
<td>Nonprimary surgical procedure to other regional sites</td>
</tr>
<tr>
<td>3</td>
<td>Nonprimary surgical procedure to distant lymph nodes</td>
</tr>
<tr>
<td>4</td>
<td>Nonprimary surgical procedure to distant site</td>
</tr>
<tr>
<td>5</td>
<td>Combination of codes</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

*FORDS Page 142
Radiation Therapy

- Regional treatment modality (FORDS page 155)
  - Type of regional radiation dose delivered to the primary volume (area) of interest
- Boost treatment modality (FORDS page 159)
  - Type of radiation provided to a smaller volume within the same volume as regional radiation

Cervix

- Radiation therapy plus chemotherapy
  - Intracavitary radiation and External Beam Radiation Therapy to the pelvis combined with cisplatin or cisplatin/fluorouracil or standard treatment options depending on the size of the tumor and stage.

Cervix

- Intracavitary radiation
  - Low Dose Radiation
    - Typically intracavitary (51)
    - May be interstitial (53)
  - High Dose Radiation
    - Intracavitary (52)
- External Beam Radiation
  - May be done in combination with brachytherapy
  - Often done using 3D CRT (32) or IMRT (31)
### Regional Treatment Modality

#### Uterine body cancer
- **External beam radiation**
  - Codes 20–30: Orthovoltage, cobalt, photons, electrons, or neutrons
  - Code 31: Intensity modulated radiation therapy (IMRT)
  - Code 32: Conformal radiation

#### Brachytherapy
- Vaginal cylinder
  - Code 50: Brachytherapy, NOS
  - Codes 51: Low dose rate intracavitary brachytherapy
  - Code 52: High dose rate intracavitary brachytherapy

#### Ovarian cancer
- Intraperitoneal Phosphorus 32 (P-32)
  - Code 60: Radioisotopes, NOS
Chemotherapy

- **Cervical Cancer**
  - May be given concurrently with radiation
  - Cisplatin
  - Cisplatin with fluorouracil.

Chemotherapy

- **Uterine body cancer**
  - Systemic single and multi-agent
    - Doxorubicin
    - Cisplatin
    - Paclitaxel
  - Ovarian cancer
    - Intraperitoneal single and multi-agent
      - Cisplatin
      - Paclitaxel
      - Systemic single and multi-agent
        - Cisplatin
        - Carboplatin and paclitaxel

Hormone Therapy

- **Uterine body cancer**
  - Progestational agents
    - Hydroxyprogesterone, medroxyprogesterone, megestrol
  - Antiestrogens
    - Tamoxifen
- **Ovarian cancer**
  - Antiestrogens
    - Tamoxifen
Female Reproductive Sites

Immunotherapy

- Ovarian cancer
  - Intraperitoneal radioimmunoconjugates
  - Gene therapy

Questions?

- The Commission on Cancer has asked that all questions to the I&R be sent from NAACCR.

Thank You!
Thank you for participating in the NAACR Hospital Registry Webinar Series!

Our next Central Registry Webinar will be “Hospital Cancer Registry Operations” on 1/10/07.

Jim Hofferkamp
jhofferkamp@naaccr.org

Shannon Vann
svann@naaccr.org